BRAF and melanoma: We used inour study, two melanoma cell lines, since the malignant WM266-4 linecarries a BRAF p.V600E substitutionmissense mutation (ENST00000288602.11). We compared spheroids’ and tumorspheres’morphology and preclinically designed end points such as viabilitytests (PI imaging of necrotic core, PI/Annexin V flow cytometry, trypanblue staining).